Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus MP108
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus MP108 is a proprietary probiotic bacterial strain originally isolated from the feces of healthy infants. It has been developed and commercialized as a probiotic ingredient for use in food supplements, infant nutrition products, and functional foods. The mechanism of action is primarily through modulation of the gut microbiota, enhancement of intestinal barrier function, anti-inflammatory effects, and antioxidant activity. Clinical studies have demonstrated its efficacy in reducing symptoms associated with atopic dermatitis and allergic rhinitis in children as well as improving outcomes in hemolytic jaundice models by ameliorating liver function and oxidative stress markers[3][5][6]. Toxicological evaluations indicate that it is safe for human consumption with no evidence of genotoxicity or adverse effects at high doses[1][8]. The strain has received regulatory approvals for use in infant foods in China and Taiwan and holds multiple patents globally[2][9].
- Brand names
- BioflagPRONULIFE
- Other names
- L. rhamnosus MP108Lactobacillus rhamnosus strain MP108
Beyond the preview
Go deeper on lactobacillus rhamnosus MP108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus MP108.